Aro Biotherapeutics
Philadelphia
About Aro Biotherapeutics
Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $166.5M
- Funding stage: Early Stage Venture
- Last round: Series B (Nov 2023)
- Website: arobiotx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aro-biotherapeutics-36793 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.